Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
0.2508 x 200 0.2648 x 1,000
Post-market by (Cboe BZX)
0.2612 +0.0064 (+2.51%) 04/21/25 [NYSE Arca]
0.2508 x 200 0.2648 x 1,000
Post-market 0.2564 -0.0048 (-1.84%) 17:12 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2501
Day High
0.2671
Open 0.2599
Previous Close 0.2548 0.2548
Volume 541,300 541,300
Avg Vol 1,564,945 1,564,945
Stochastic %K 54.95% 54.95%
Weighted Alpha -86.43 -86.43
5-Day Change -0.0448 (-14.64%) -0.0448 (-14.64%)
52-Week Range 0.1800 - 2.3900 0.1800 - 2.3900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,435
  • Shares Outstanding, K 84,124
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,920 K
  • EBIT $ -27 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.69
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.48
  • Most Recent Earnings $-0.11 on 02/14/25
  • Next Earnings Date 05/15/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 357.61% ( +41.33%)
  • Historical Volatility 149.19%
  • IV Percentile 83%
  • IV Rank 35.98%
  • IV High 976.07% on 04/10/25
  • IV Low 10.05% on 08/14/24
  • Put/Call Vol Ratio 0.01
  • Today's Volume 75
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 4,021
  • Open Int (30-Day) 10,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +713,671.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1800 +45.11%
on 04/09/25
Period Open: 0.2600
0.3200 -18.37%
on 04/11/25
+0.0012 (+0.46%)
since 03/21/25
3-Month
0.1800 +45.11%
on 04/09/25
Period Open: 0.3937
0.6803 -61.61%
on 02/20/25
-0.1325 (-33.66%)
since 01/21/25
52-Week
0.1800 +45.11%
on 04/09/25
Period Open: 1.5600
2.3900 -89.07%
on 05/08/24
-1.2988 (-83.26%)
since 04/19/24

Most Recent Stories

More News
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz

/CNW/ -- Equity Insider News Commentary – Routine medical appointments or cancer screenings—critical for catching the disease in earlier, more treatable...

ONCY : 0.5750 (+2.50%)
ONC : 229.22 (-0.76%)
CVM : 0.2612 (+2.51%)
ONC.TO : 0.79 (+2.60%)
ATNM : 1.2000 (-0.83%)
OSTX : 1.4900 (-2.61%)
Cel-Sci Stock Slips After Public Offering: Retail's Neutral

The purchase price of each pre-funded Warrant is equal to the price per share of common stock being sold to the public in this offering, minus $0.01.

IWC : 102.60 (-1.87%)
VXF : 158.14 (-2.32%)
VTI : 252.60 (-2.38%)
CVM : 0.2612 (+2.51%)
Have a Relaxing Holiday Season

Monday U.S. Economic Lookahead Consumer confidence (Dec.) Featured Earnings Limoneira ...

OTLK : 1.4700 (+1.38%)
PFX : 50.10 (-0.16%)
LMNR : 15.70 (-1.97%)
CVM : 0.2612 (+2.51%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.5750 (+2.50%)
PYXS : 1.0600 (+10.04%)
RPTX : 1.2000 (unch)
IMRX : 1.3800 (+8.66%)
CVM : 0.2612 (+2.51%)
ONC.TO : 0.79 (+2.60%)
Goodbye ’23

Monday U.S. and Canada Christmas Day, Markets Closed Tuesday U.S. Economic ...

CTXR : 0.8600 (-11.16%)
CVM : 0.2612 (+2.51%)
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

TCBP : 0.5000 (-67.53%)
CVM : 0.2612 (+2.51%)
INVO : 0.8330 (-2.91%)
PFE : 22.04 (-0.45%)
SNY : 50.93 (+0.06%)
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public...

CVM : 0.2612 (+2.51%)
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Corporation (NYSE American: CVM) today announced it has held a productive pre-submission meeting with Canada’s regulator to determine the best regulatory path toward market approval. Based...

CVM : 0.2612 (+2.51%)
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension

CEL-SCI Corporation (NYSE American: CVM) today reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head...

CVM : 0.2612 (+2.51%)
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology

CEL-SCI Corporation (NYSE American: CVM) today announced it will present new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma...

CVM : 0.2612 (+2.51%)

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

3rd Resistance Point 0.2858
2nd Resistance Point 0.2765
1st Resistance Point 0.2688
Last Price 0.2612
1st Support Level 0.2518
2nd Support Level 0.2425
3rd Support Level 0.2348

See More

52-Week High 2.3900
Fibonacci 61.8% 1.5458
Fibonacci 50% 1.2850
Fibonacci 38.2% 1.0242
Last Price 0.2612
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro